Insulin glargine biosimilar (Lilly/Boehringer Ingelheim)

甘精胰岛素生物类似药 (Lilly/Boehringer Ingelheim)

Report date: 2026/03/23 20:03:44

Base Information

Drug NameInsulin glargine biosimilar (Lilly/Boehringer Ingelheim)
Drug Alias NameInsulina glargina (Lilly/Boehringer Ingelheim)甘精胰岛素生物仿制药 (Lilly/Boehringer Ingelheim)Insulinum glarginum (Lilly/Boehringer Ingelheim)Insuline glargine (Lilly/Boehringer Ingelheim)insulin glargine-aglr +[12] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant hormone
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsHyperglycemiaDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1 +[5] 
Global Approved IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus
Approved Indications in ChinaDiabetes Mellitus
Original Approved Country/TerritoryEU
Original Approved Date2014/09/09
Country/TerritoryCzechiaBelgiumCanada +[36] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBoehringer Ingelheim International GmbhEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesLilly France SasEli Lilly And CompanyEli Lilly Regional Operations Gmbh +[5] 
Inactive CompaniesC.H. Boehringer Sohn Ag & Co. KgSanofiNovo Nordisk A/S +[6] 
Active IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus
Inactive IndicationsHyperglycemiaRenal Insufficiency, Chronic

Other Information

ATC CodeA10AE04
Related LinksWikipediaDrugBankKEGG